Charles Garvey (CEO)
Charles Garvey is a serial entrepreneur with extensive experience in growing Irish technology companies internationally. From 1990 to 2003 he was first COO and then CEO of Horizon Technology Group Plc. and took Horizon from a small privately held company to a major European multinational with significant global credentials. The group became Sun Microsystems largest partner in Europe, the largest distributor of PCs in the Irish Market. IBM’s fastest growing partner in the UK, Oracle’s exclusive distributor in the UK, Cisco System’s largest training partner in Europe, SAP’s largest independent consulting firm in Ireland and a host of other accolades including the largest contract software developer in Ireland. Charles took Horizon public on the London and Dublin stock exchange. He has extensive M&A experience handling over 13 acquisitions and disposals. The company achieved a market capitalization worth over €1b and employed 720 people in 5 countries through 13 separate companies. Charles continued to work with Horizon right up to its sale to Avnet Corp in 2009.
From 2006 to 2011 Charles has been CEO of a technology startup where he grew the business to over 800 clients worldwide.
Charles is a mentor to several high potential startups and has extensive experience at forging and managing partnerships with major multinational companies and in corporate finance and fundraising through angel investors, VCs, banks and public markets.
Prof. Philip Baker (Director Of Research)
In 2015 Philip Baker was appointed Pro-Vice-Chancellor, Head of the College of Medicine, Biological Sciences and Psychology and Dean of Medicine at the University of Leicester, with Honorary Consultant Obstetrician status at the University of Leicester Hospitals NHS Trust.
Prior to accepting the position in Leicester Professor Baker lived and worked in New Zealand where he served as Director of the National Research Centre for Growth and Development and held the position of Professor of Maternal & Fetal Health at the University of Auckland.
Professor Baker also runs a dedicated pregnancy research centre based in Chongqing Medical University in Western China following his appointment as a National Distinguished Professor by the Chinese Government in 2013.
Previously Professor Baker led the medical schools in both Manchester, UK and Alberta, Canada. He also established and then directed the Manchester NIHR Biomedical Research Centre. He has held visiting professorial appointments in Hong Kong, Toronto and Yale.
In 2005 he was given the President’s Achievement Award of the Society of Gynecologic Investigation (The first time this award had been made outside North America). He was elected a Fellow of the Academy of Medical Sciences in 2008.
He is a world authority in the etiology and management of pre-eclampsia, having published over 300 scientific articles and 13 textbooks (including the leading UK undergraduate and postgraduate obstetric texts). He has been investigating screening tests for pre-eclampsia for over 20 years. He been awarded grants totaling over £14M for his own research portfolio and he is currently co-PI of an MRC program grant and a Wellcome Trust Translational award. He has led institutional research applications that have successfully accrued >£50M.
He was principal author of the position paper on “Health of Women and Children”, presented to The Science Academies of the G8 countries, and considered at the G8 Summit held in Huntsville, Ontario, in June 2010.
Prof. Louise Kenny
Louise Kenny (MB ChB (hons), PhD, MRCOG) is Professor of Obstetrics at University College Cork and a Consultant Obstetrician and Gynaecologist at Cork University Maternity Hospital. Louise has a longstanding clinical and research interest in uteroplacental insufficiency, adverse pregnancy outcome and pregnancy loss. Louise is arguably the world’s leading exponent of the application of metabolomic technologies for patient benefit. Louise is currently coordinating a multinational study of the clinical exploitation of metabolomic technologies involving the Universities of Alberta (Canada), Manchester (UK) Adelaide (Australia) and Auckland (New Zealand).
Louise has developed international collaborative research programs with the Universities of Zhejiang (China) and Aarhus (Denmark) and with the Karolinska Institute (Sweden).
Since her appointment in 2006 at the new Anu Research Centre at Cork University Maternity Hospital, Louise has raised over €5 million in external awarded peer reviewed grants and has developed a research group consisting of more than 20 researchers from a wide variety of clinical and scientific disciplines. In 2007, Louise was appointed as a Health Research Board Ireland Clinician Scientist. She is the PI and custodian of the SCOPE Ireland (www.scopestudy.net) and the BASELINE Birth Cohort (baslinestudy.net) biobanks.
In July 2009, Louise was awarded a Principal Investigator Program grant from Science Foundation Ireland to develop predictive metabolomic markers of poor pregnancy outcome. In addition she currently holds a translational award from The Wellcome Trust and funding from The Children’s Medical and Research Foundation, Molecular Medicine Ireland, the Health Research Board of Ireland and FP7.
Louise’s work has resulted in >100 peer reviewed original papers, reviews and book chapters. She is the Editor of the 19th Edition of ‘Obstetrics by Ten Teachers’- the world’s leading undergraduate textbook in obstetrics. In addition, Louise is a reviewer for a wide range of international journals and research funding bodies and is a member of the RCOG Wellbeing of Women Scientific Advisory committee.
Diarmuid Cahalane has been consulting to the technology and life sciences sectors for over 20 years. He is recognised for his strengths in risk analysis, remediation, cost reduction and compliance. In 1997, he established his own regulatory consulting company, and went on to work with many of the leading life science companies, including Pfizer, Schering Plough, and Glaxo Smithkline.
His level of expertise in Medical Devices is particularly strong given that he has worked on validation of software as a medical device with Guidant, Johnson & Johnson, and Nellcor Puritan Bennett. He contributed to the Pharmaceutical Industry Computer Systems Validation Forum (PICSVF) in 1994, which subsequently became known as the Good Automated Manufacturing Practice (GAMP) forum. In 1997 he participated in meetings with the FDA prior to the publication of 21 CFR Part 11. In 1999, he signed a global professional services agreement with Schering Plough, which led to his company completing projects in Singapore, US, and Germany as part of a global Computer Systems Validation Remediation Project.
Diarmuid has also successfully provided accreditation services to hospitals enabling them to get their pathology laboratories accredited to ISO15189 Quality Standards. Hospital clients included the Mater Private, St. James’s, Beaumont, The Bon Secours Health System, St. Lukes, The National Orthopaedic Hospital, The National Children’s Hospital and many others. He has presented guest lectures to students in the Department of Process Engineering at University College Cork, and also at St.James’s Hospital in Dublin. His company, Open Innovation Partners, is part of a European Consortium, “BioApp- Biodesign For Health” which aims to integrate innovation into the undergraduate curriculum across Europe through formulated design methodologies leading to accelerated application of Biomedical Technologies in the Clinical Setting. Funded by the European Union, the project is led by University College Cork, in conjunction with Universities in the Netherlands, Belgium, and Hungary.
Diarmuid is a regular speaker at major Business conferences including the European Compliance Academy in Germany and validation conferences in Puerto Rico and the US. He maintains contact with the FDA at a high level and recently visited Washington DC to discuss innovative new theranostics concepts with the FDA, Patient Advocacy Groups and others. He spoke at the International Critical Markers Of Disease (CMOD) Conference in Dublin Castle in May 2012, the EU-US Standardisation Conference in the RCSI in February of this year, and most recently at the SMEST Conference in Brussels, Belgium.
Robin Tuytten serves as Vice President Research and Development of Metabolomic Diagnostics Ltd. and its parent company InformBio. Robin has a PhD in Chemistry and has been involved in biomarker discovery and development for nearly a decade. Robin has been leading preeclampsia biomarker discovery programs in several start-up companies, and is a co-inventor on several preeclampsia protein biomarker patent applications.